Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.

Clin Breast Cancer

Sorokoa Cancer Institute, Ben Gurion University, Beer-Sheva, Israel. Electronic address:

Published: June 2018

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.clbc.2017.11.017	DOI Listing

Publication Analysis

rapid response

response larotrectinib

larotrectinib loxo-101

loxo-101 adult

adult chemotherapy-naive

chemotherapy-naive patients

patients advanced

advanced triple-negative

triple-negative secretory

secretory breast

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!